key: cord-0868198-0gtrv1v3
authors: Wagner, C. E.; Saad-Roy, C. M.; Morris, S. E.; Baker, R. E.; Mina, M. J.; Farrar, J.; Holmes, E. C.; Pybus, O. G.; Graham, A. L.; Emanuel, E. J.; Levin, S. A.; Metcalf, C. J. E.; Grenfell, B. T.
title: Vaccine nationalism and the dynamics and control of SARS-CoV-2
date: 2021-06-05
journal: nan
DOI: 10.1101/2021.06.02.21258229
sha: 8085c76b9555ed456fb8ccb469aacc1924c4fcc5
doc_id: 868198
cord_uid: 0gtrv1v3

Vaccines provide powerful tools to mitigate the enormous public health and economic costs that the ongoing SARS-CoV-2 pandemic continues to exert globally, yet vaccine distribution remains unequal between countries. To examine the potential epidemiological and evolutionary impacts of 'vaccine nationalism', we extend previous models to include simple scenarios of stockpiling. In general, we find that stockpiling vaccines by countries with high availability leads to large increases in infections in countries with low vaccine availability, the magnitude of which depends on the strength and duration of natural and vaccinal immunity. Additionally, a number of subtleties arise when the populations and transmission rates in each country differ depending on evolutionary assumptions and vaccine availability. Furthermore, the movement of infected individuals between countries combined with the possibility of increases in viral transmissibility may greatly magnify local and combined infection numbers, suggesting that countries with high vaccine availability must invest in surveillance strategies to prevent case importation. Dose-sharing is likely a high-return strategy because equitable allocation brings non-linear benefits and also alleviates costs of surveillance (e.g. border testing, genomic surveillance) in settings where doses are sufficient to maintain cases at low numbers. Across a range of immunological scenarios, we find that vaccine sharing is also a powerful tool to decrease the potential for antigenic evolution, especially if infections after the waning of natural immunity contribute most to evolutionary potential. Overall, our results stress the importance of equitable global vaccine distribution.

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Vaccines provide powerful tools to mitigate the enormous public health and 1 economic costs that the ongoing SARS-CoV-2 pandemic continues to exert 2 globally, yet vaccine distribution remains unequal between countries. To ex-3 amine the potential epidemiological and evolutionary impacts of 'vaccine na-4 tionalism', we extend previous models to include simple scenarios of stock-5 piling. In general, we find that stockpiling vaccines by countries with high The SARS-CoV-2 pandemic has led to more than 100 million infections and nearly 3 million 24 fatalities to date (1) . Effective vaccines (e.g. (2-4)) have now been approved and are actively 25 being deployed, but numerous important questions remain. Eventually, community immunity 26 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint may be attained through the deployment of vaccines; however if and when this occurs will be 27 contingent on the characteristics of natural and vaccinal immunity (5-7) in conjunction with 28 SARS-CoV-2 evolutionary potential. initiative. Furthermore, to ensure that vaccine distribution is ethically-sound and equitable, the 41 "Fair Priority Model" has been proposed (11-13) as a potential replacement to the currently 42 planned proportional allocation (by population size) from COVAX.

Prior work exploring optimal prophylactic vaccine allocation for minimizing the final epi-45 demic size of a fully immunizing infection (i.e. one that can be modeled using a susceptible-46 infected-recovered (SIR) framework) found that when interaction between communities (or 47 countries) is considered, equal vaccine distribution is increasingly advantageous in terms of CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint coalition formation (18), and for SARS-CoV-2 with age-(and contact-) structure (19, 20). We 53 have recently shown that the strength and duration of immunity elicited following infection or 54 one or two doses of a vaccine will have a crucial impact on the medium-term epidemiological 55 and potential evolutionary outcomes (5, 6). Here we extend these analyses to address potential 56 epidemiological and evolutionary consequences of policies of vaccine nationalism or equitable 57 access for a range of assumptions regarding the robustness of host immune responses. In real-58 ity, vaccine distribution is a public goods problem, and the optimal "global" allocation projected 59 based on evolutionary and immunological uncertainties may differ from national optima due to 60 the actual economic landscape of each country. In all cases, however, the reduction in the po-61 tential for novel strains to arise associated with minimizing the global infection burden is likely 62 critical. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint Figure 1 : Schematic depicting the two-country model. The underlying immuno-epidemiological models for each country are based on (5, 6). Vaccines are allocated by the high access region (HAR) to the low access region (LAR). In the coupled framework, immigration of infected individuals between the countries is considered, and the national transmission rate depends on potential transmission increases (PTIs) in both countries, shown schematically as solid and striped virus particles in the HAR and LAR, respectively. In the decoupled framework, no immigration occurs, and the transmission rate is not influenced by PTIs. Full model details are provided in the Supplementary Materials.

We consider a trans-national extension of our model comprised of two countries with possi-65 bly different population sizes and seasonal transmission patterns. One country, the high access 66 region (HAR), chooses to allocate a fraction f of the total vaccine supply to the low access 67 region (LAR). The underlying immuno-epidemiological models for both countries account for 68 both the duration of natural and vaccinal immunity and the residual decrease in host suscepti-69 bility to infection (relative to immunologically naive individuals) after full natural or vaccinal 70 immunity has waned; these models are described in detail in (5, 6), where the more detailed 71 structure (6) accounts for immunity after one or two vaccine doses. In the first "decoupled" 72 framework (top panel of Figure 1 ), we assume that the epidemiological dynamics of both coun-73 5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint tries are entirely independent with the exception of their respective vaccination rates, and we 74 also compute a measure for the global potential for viral evolution of immune escape (6). In the 75 second "coupled" framework (bottom panel of Figure 1 ), we allow for immigration of infected CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint reproduction numbers. We do so for total as well as severe cases, with the expectation that the CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint When the characteristics of both countries are the same, sharing vaccines always decreases 126 or maintains the total fraction of infections at the long-term equilibrium (see Keeling (14) for 127 the SIR extreme with a focus on two differently-sized populations). The intuition for this result 128 is apparent from examining the underlying values for each country ( Figure 2C ). The total frac- is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. Figure 2 : Long-term equilibrium of the average fraction of infections. In all panels, immunity scenarios are as follows: very poor immunity, 1 δ = 1 δvax = 0.8 years, = 0.8; poor immunity, 1 δ = 1 δvax = 1 year, = 0.7; intermediate immunity,

In the scenario with asymmetrical transmission rates between the two countries, the transmission rate in the country with lower transmission is taken to be 80% of the value in the symmetric case. In the scenarios with overall higher transmission rates (panel B), this same asymmetric assumption is made in addition to the baseline symmetric transmission rate being elevated by 30% relative to the value in panels (A). (C)-(E) Illustrations of the equilibrium fraction of infections in each country with the very poor immunity scenario, for: (C) symmetric transmission with ν tot = 0.004; (D) asymmetric transmission (lower in HAR) with ν tot = 0.004; (E) asymmetric transmission (lower in HAR) with ν tot = 0.001; with all other parameters as in panel A. In all panels, the baseline transmission rate is β = 2.3 5 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 1 . In all panels, vaccination begins after week 48. Poor vaccinal immunity after one dose is represented by 1 δ1 = 0.25 year and 1 = 0.9, whereas robust vaccinal immunity after one dose means 1 δ1 = 1 year and 1 = 0.7. All other parameters values including the procedure for the calculation of severe cases are described in Supplementary Materials. In both the top and bottom panels: the top row depicts a switch from a maximum first-dose administration rate of 1% to 3% after week 60, whereas it is 1% to 5% for the bottom row (and concurrent with sharing, if it occurs).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint cumulation of individuals with waned one-dose immunity and thus potentially larger infections 177 peaks in the longer term (top panel, Figure 3 ). If poor one-dose immunity nevertheless reduces 178 severity of infection after waning (unlike our pessimistic assumption), then the predicted clin- CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint in hosts with natural immunity, then sharing vaccines always decreases global evolutionary po-203 tential ( Figure S3 ) in the decoupled framework. Overall, when immunity after a single vaccine 204 dose is robust, natural and vaccine-derived immunity will limit evolutionary advances relative of SARS-CoV-2, particularly the variants of concern, are of considerable public health impor-221 tance. Thus, we next explore these effects using the coupled framework presented in the bottom 222 panel of Figure 1 . period. We do so for various vaccine allocation fractions between the HAR and LAR, as well 229 as a range of immigration rates assuming symmetric transmission rates (Figures 4A and 4C ) 230 and relative mean reproduction numbers assuming constant immigration rates ( Figures 4B and   231 4D, see Methods). In Figures 4A and 4B we assume that infection following waned natural 232 immunity contributes the most to viral adaptation, while in Figures 4C and 4D we assume that 233 infection following waned vaccinal immunity, and one-dose immunity in particular, contributes 234 the most. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint Figure 4 : Heat maps depicting total and severe cases from the time of vaccine onset (t vax = 48 weeks) through the end of the 5 year period for both countries (leftmost two columns), the HAR (third and fourth columns from the left), the LAR (fifth and sixth columns from the left), as well as the combined number of PTIs to have occurred in both countries at the end of 5 years (rightmost column). Each grid-point denotes the mean value of 100 simulations. The population of both countries is taken to be the same. Each area plot is internally normalized, such that the largest value in each plot is 1. The x-axis indicates the fraction of vaccines retained by the HAR (i.e. 1 − f ); thus the far right of a plot is the scenario where the HAR retains all vaccines (f = 0). In A and C, both countries have the same average transmission rate (R 0 , see Methods), and the immigration rate η is varied. In B and D, the immigration rate is fixed at η = 0.01, and the relative mean transmission rate in the LAR, i.e.R 0,LAR /R 0,HAR , is varied between 0.5 and 2. The seasonality of the transmission rates in both countries and periods of NPI adoption are identical and as described in the Methods. In all simulations, we assume a two-dose strategy throughout, i.e. 1 ω = 4 weeks, and take the maximal rate of administration of the first dose to be ν 0,tot = 2%. Assumed immunological parameters are 1 δ1 =1 year, = 0.7,

ρ2 =1 year, and the one-to two-dose immune response ratio is x e = 0.8 (see Methods). In the top panel (A and B) , we assume that infection after waned natural immunity contributes more to potential viral adaptation, and take w IS = 0.8, w IS1 = 0.2/x e , and w IS2 = 0.2 (see Methods). In the bottom panel (C and D), we assume that infection after waned vaccinal immunity contributes more to potential viral adaptation, and take w IS = 0.4, w IS1 = 0.8, and w IS2 = 0.8 × x e (see Methods). Additional details related to the determination of severe cases are also provided in Supplementary Materials.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint For equal population sizes and symmetric transmission rates, a weak dependence of total 236 and severe cases as well as PTIs on the immigration rate η is observed, regardless of whether 237 infection after waned natural or vaccinal immunity is assumed to contribute more to viral evo-238 lution (Figures 4A and4C) . Additionally, equal vaccine sharing (i.e. f = 0.5) minimizes total 239 PTIs and combined total cases in both scenarios. When natural infections contribute more to 240 evolution ( Figure 4A ) and η is low, the HAR must retain an increasing share of the vaccines to 241 minimize local total cases as the immigration rate increases, but this is done at the expense of For the same total vaccine availability, the most realistic population asymmetry is that the 251 LAR has a larger population; this corresponds to low and middle income countries with more 252 fragile healthcare systems. Under this condition ( Figure S4 ) and when infection after waned 253 natural immunity contributes more to evolution, total cases in the LAR are relatively insen- CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint metric population sizes, and more equitable vaccine sharing is favoured for both vaccination 262 rates ν 0,tot given a larger population in the LAR (Figures S4 and S5) .

When the LAR has a smaller population ( Figure S6 ), a relatively weak dependence of total 265 and severe case numbers and PTIs on η is still observed for both evolutionary scenarios, par-266 ticularly for higher immigration rates. However, and particularly when infection after waned 267 natural immunity contributes more to evolution, the minima in combined cases and PTIs are 268 now observed for f < 0.5, i.e. when the HAR retains more than half of the available vaccines.

Importantly, we note that additional booster doses may further change these landscapes of im-270 munity, and consequently the projected burdens of total and severe cases. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint and vaccine supply is sufficiently high to reduce case numbers in the LAR, PTIs are numerous 288 when the HAR retains a large fraction of the vaccines (Figures 4B, S5B, and S6B ). This is due In all simulations, we takeR 0,LAR /R 0,HAR = 1.2, η = 0.01, and assume that infection after waned natural immunity contributes primarily to evolution (i.e. w IS = 0.8, w IS1 = 0.2/x e , and w IS2 = 0.2). All other parameters are identical to those in Figure 4 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint

We note that assumptions of largeR 0 in the LAR also result in very large initial infection 297 peaks, which increase community immunity in the medium-term. These initial waves are not 298 reflected in the total case counts, however, since these values are summations from the time of does not increase transmission rates in either the HAR or LAR. Overall, we show that vaccines 317 play an important role in minimizing cases (particularly severe cases) as well as potential viral 318 adaptation in both regions. We also emphasize that imperfect vaccinal and natural immunity 319 and asymmetries in population size and transmission rates add many nuances to this picture. 320 20 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. in future models will be important for qualitative and quantitative predictions. Additionally, 329 we omit vaccine hesitancy (32), though simple extensions of our previous models with hesi-330 tancy (5, 6) could examine the resulting interplay with vaccine nationalism. Furthermore, we 331 have assumed the simplest evolutionary models, both for determining potential viral adaptation 332 rates as well as for simulating potential increases in transmission rates. As more data become CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The Lancet Infectious Diseases

Proceedings of the National Academy of Sci-403 ences

the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

doi: medRxiv preprint 21

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 5, 2021. ; https://doi.org/10.1101/2021.06.02.21258229 doi: medRxiv preprint